FREE FEDEX 2-DAY SHIPPING OVER $200Same-Day Dispatch Before 1 PM ETThird-Party TestedBatch COAs Available
FOR LABORATORY RESEARCH USE ONLY — NOT FOR HUMAN OR VETERINARY USE
Peptide Pilots
Log in

Research library

NAD+ Research Overview: Biosynthetic Pathways, Sirtuin and PARP Consumption, and Human Trial Evidence

Compiled by:
Peptide Pilots Scientific Content Team
Reviewed by:
Peptide Pilots Quality & Compliance review
Last revised:

What does published research establish about NAD+ biology, and what do human precursor trials actually show?

NAD+ is a redox cofactor and enzyme substrate central to glycolysis, the TCA cycle and oxidative phosphorylation, and it is consumed rather than merely cycled by sirtuins, PARPs and CD38. Tissue NAD+ decline with age is reported in multiple model systems and in some human tissues. Human trials of the precursors nicotinamide riboside and nicotinamide mononucleotide consistently report increases in blood NAD+ metabolites, but functional clinical endpoints have been inconsistent and mostly derived from small, short studies. NAD+ itself is a poorly membrane-permeant molecule, so direct-administration research is not equivalent to precursor research.

This page is an educational literature summary for laboratory professionals. It is not medical advice, not a description of product performance, and it does not describe or endorse human or veterinary use. Materials referenced are supplied for controlled laboratory research only.

What is NAD+ (nicotinamide adenine dinucleotide)?

NAD+ is a dinucleotide composed of nicotinamide mononucleotide linked to adenosine monophosphate. It cycles between oxidised (NAD+) and reduced (NADH) forms in redox reactions, and it is cleaved at the glycosidic bond by NAD-consuming enzymes, releasing nicotinamide.

In laboratory work NAD+ and its precursors are used in enzymology (sirtuin and PARP assays), metabolomic quantification of the NAD metabolome, cell-culture rescue experiments, and animal models of metabolic and neurodegenerative phenotypes.

NAD+ (nicotinamide adenine dinucleotide) names and identifiers

Also referred to as: nicotinamide adenine dinucleotide; β-NAD; DPN (diphosphopyridine nucleotide); coenzyme I

Molecular formulaC21H27N7O14P2
Average molecular weight≈663.43 g/mol
CAS number53-84-9 (free acid, oxidised form)
Database recordsPubChem CID 5892; ChEBI:15846; KEGG C00003
Biosynthetic routesSalvage (NAMPT/NMNAT), Preiss-Handler (nicotinic acid), de novo from tryptophan via the kynurenine pathway
Principal consumersSirtuins (SIRT1-7), PARPs, CD38/CD157, SARM1

NAD+ (nicotinamide adenine dinucleotide) research background

The cofactor was described by Harden and Young in 1906 as a heat-stable fermentation factor, later structurally characterised, with Warburg establishing its hydride-transfer role in the 1930s.

Modern interest shifted from redox chemistry to NAD+ as a consumed substrate after the discovery that sirtuin deacetylases and PARP DNA-repair enzymes cleave NAD+, coupling metabolic state to gene regulation and genome maintenance.

Reports that tissue NAD+ declines with age, and that CD38 expression rises with age, produced the current research programme: whether restoring NAD+ availability through precursors alters age-associated phenotypes. This remains the central open question.

Proposed NAD+ (nicotinamide adenine dinucleotide) mechanisms and pathways

Evidence is separated by study type. In-vitro and animal findings describe model systems and do not establish equivalent behaviour in humans.

NAD+ (nicotinamide adenine dinucleotide) in-vitro and cell-based evidence

  • NAD+ serves as hydride acceptor in dehydrogenase reactions and as ADP-ribose donor for sirtuins and PARPs; sirtuin activity in vitro is sensitive to both NAD+ concentration and nicotinamide product inhibition.
  • Cell-culture studies report that NAMPT inhibition depletes NAD+ and impairs mitochondrial function, an effect rescued by NMN or NR supplementation.
  • Extracellular NAD+ is poorly transported across the plasma membrane in most cell types and is largely degraded by ectoenzymes such as CD38 and CD73 before uptake as smaller metabolites.

NAD+ (nicotinamide adenine dinucleotide) animal-model evidence

  • Rodent studies report NAD+ decline with age in liver, muscle and brain, and improvements in mitochondrial and metabolic markers following precursor administration.
  • SARM1-mediated NAD+ depletion has been established as a driver of axon degeneration, one of the better-defined causal roles for NAD+ loss.
  • Effects on lifespan in mammals are inconsistent; several rodent studies report healthspan-associated changes without lifespan extension.

Published NAD+ (nicotinamide adenine dinucleotide) human-study evidence

  • Randomised trials of nicotinamide riboside and nicotinamide mononucleotide reliably report dose-dependent increases in whole-blood NAD+ metabolites.
  • Functional endpoints — insulin sensitivity, muscle mitochondrial function, exercise capacity, inflammatory markers — have shown inconsistent results across trials, with several well-conducted studies reporting no significant change.
  • Direct intravenous NAD+ research in humans is limited to small studies, with pharmacokinetic work indicating rapid metabolism to nicotinamide and related metabolites.

Published NAD+ (nicotinamide adenine dinucleotide) studies

Selected published studies involving NAD+ (nicotinamide adenine dinucleotide)
StudyModel / typeResearch questionMain observationCitation
Trammell et al., NR pharmacokineticsHuman, crossover pharmacokinetic studyDoes oral nicotinamide riboside raise the NAD metabolome?Dose-dependent increases in blood NAD+ and related metabolites were reported.Nature Communications, 2016
Elhassan et al., aged muscle trialHuman, 21-day randomised trial in older menDoes NR change muscle mitochondrial bioenergetics?NAD metabolome increased in muscle, but mitochondrial bioenergetics and functional endpoints were largely unchanged.Cell Reports, 2019
Camacho-Pereira et al., CD38 and NAD declineMouse tissues and CD38-knockout modelsWhat drives age-related NAD+ decline?Increased CD38 expression with age was reported as a major consumer contributing to NAD+ decline.Cell Metabolism, 2016
Gerdts / Essuman SARM1 workNeuronal injury modelsIs NAD+ depletion causal in axon degeneration?SARM1 was characterised as an NAD+-cleaving enzyme whose activation triggers axon degeneration, establishing a causal NAD+ mechanism.Neuron, 2017

Limitations of the NAD+ (nicotinamide adenine dinucleotide) evidence

  • Raising blood NAD+ metabolites is a biomarker outcome, not a clinical outcome; trials that report the former frequently fail to demonstrate the latter.
  • Tissue-level NAD+ changes are difficult to measure in humans, and blood measurements may not represent muscle, brain or liver pools.
  • Human trials are typically small (tens of participants) and short (2–12 weeks), which is poorly matched to the age-related processes being studied.
  • NAD+ itself is not efficiently taken up by cells; extrapolating precursor findings to direct NAD+ administration is not supported by the pharmacology.
  • Publication and sponsorship bias is a real concern in this field, given the size of the consumer supplement market built on these findings.
  • Reported NAD+ decline with age varies by tissue and by measurement method; it is not a uniform or universally reproduced finding.

NAD+ (nicotinamide adenine dinucleotide) laboratory characteristics

Handling and analytical information reported in the literature and in supplier documentation. Values apply to laboratory materials and are not directions for any other use.

AppearanceWhite to off-white hygroscopic powder
SolubilityFreely soluble in water; solutions are typically prepared fresh
Lyophilised storageCommonly stored at −20 °C, desiccated; the compound is notably hygroscopic
Reconstituted handlingAqueous solutions degrade at alkaline pH and elevated temperature; cold, near-neutral handling is standard
Analytical testingPurity by HPLC with UV detection at 260 nm; identity by MS; enzymatic cycling assays used for quantification in biological matrices
Stability considerationsHydrolysis of the nicotinamide-ribose bond and base-catalysed degradation are the primary documented routes

Frequently asked NAD+ (nicotinamide adenine dinucleotide) research questions

What is the difference between NAD+ and NADH?

They are the oxidised and reduced forms of the same dinucleotide. NAD+ accepts a hydride to become NADH; the ratio between them reflects cellular redox state.

Which enzymes consume NAD+ rather than recycle it?

Sirtuins, PARPs, CD38/CD157 and SARM1 cleave NAD+ and release nicotinamide, meaning NAD+ must be continually resynthesised, mainly by the NAMPT salvage pathway.

Do human trials show that raising NAD+ improves function?

Trials consistently show that precursors raise blood NAD+ metabolites. Functional endpoints have been inconsistent, and several well-conducted studies found no significant change.

Is NAD+ the same as NMN or NR?

No. NMN and NR are biosynthetic precursors that cells convert to NAD+. Most human trial data concern these precursors rather than NAD+ itself.

NAD+ (nicotinamide adenine dinucleotide) primary references

  1. Trammell SAJ, Schmidt MS, Weidemann BJ, et al. (2016). Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nature Communications. https://doi.org/10.1038/ncomms12948
  2. Elhassan YS, Kluckova K, Fletcher RS, et al. (2019). Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome. Cell Reports. https://doi.org/10.1016/j.celrep.2019.07.043
  3. Camacho-Pereira J, Tarragó MG, Chini CCS, et al. (2016). CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metabolism. https://doi.org/10.1016/j.cmet.2016.05.006
  4. Essuman K, Summers DW, Sasaki Y, et al. (2017). The SARM1 Toll/interleukin-1 receptor domain possesses intrinsic NAD+ cleavage activity that promotes pathological axonal degeneration. Neuron. https://doi.org/10.1016/j.neuron.2017.02.022
  5. PubMed literature index (2026). Current indexed literature for NAD+ metabolism. US National Library of Medicine. https://pubmed.ncbi.nlm.nih.gov/?term=NAD%2B+metabolism+aging

Authorship and revision

Compiled from primary literature and public databases. Every factual statement on this page is traceable to a listed reference. Compiled by Peptide Pilots Scientific Content Team; documentation and compliance review by Peptide Pilots Quality & Compliance review. First published ; last revised . Pages are revised when the cited literature changes materially.

Catalogue reference

Peptide Pilots supplies NAD+ as a laboratory reagent with per-lot RP-HPLC and mass-spectrometry documentation. Quantities, testing, packaging and fulfilment details are on the catalogue page.

View NAD+ catalogue entry